ARTICLE | Cover Story

Invigorating IVIG

October 9, 2014 7:00 AM UTC

Although IVIG has been a mainstay in autoimmune disease therapy for decades, there is still high variability in both safety and potency among different batches because the antibodies are sourced from pooled human blood. arGEN-X N.V. has developed a mutant constant region fragment of IgG1 that binds its receptor with higher affinity than IgG and has now shown that it can clear unwanted serum antibodies in nonhuman primates about 30 times more efficiently than standard IVIG.

arGEN-X's compound-ARGX-113-joins a wave of preclinical programs using recombinant approaches in a field that has seen little innovation until recently...